Articles

Ibrutinib dose modifications in the management of CLL

Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) in 2014. Ibrutinib is often used to treat patients who are younger than the patients originally ...

Authors: Camille Hardy-Abeloos, Rachel Pinotti and Janice Gabrilove

Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

An amendment to this paper has been published and can be accessed via the original article.

Authors: Bo Yu and Delong Liu

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy

Insulin-like growth factors (IGFs) play important roles in mammalian growth, development, aging, and diseases. Aberrant IGFs signaling may lead to malignant transformation and tumor progression, thus providing...

Authors: Hui Hua, Qingbin Kong, Jie Yin, Jin Zhang and Yangfu Jiang

Discovery of proangiogenic CD44+mesenchymal cancer stem cells in an acute myeloid leukemia patient’s bone marrow

Here, we report a unique acute myeloid leukemia (AML) bone marrow-derived mesenchymal stem cell (MSC) with both mesenchymal and endothelial potential, which we have named Mesenchymal Cancer Stem Cells (MCSCs)....

Authors: Huynh Cao, Jeffrey Xiao, Mark E. Reeves, Kimberly Payne, Chien Shing Chen, David J. Baylink, Guido Marcucci and Yi Xu

Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer

Expression of Oct4 maintains cancer stem cell (CSC)-like properties in lung cancer cells and is correlated with poor prognosis of lung adenocarcinoma. M2-type tumor-associated macrophages (TAMs) promote cancer...

Authors: Chia-Sing Lu, Ai-Li Shiau, Bing-Hua Su, Tsui-Shan Hsu, Chung-Teng Wang, Yu-Chu Su, Ming-Shian Tsai, Yin-Hsun Feng, Yau-Lin Tseng, Yi-Ting Yen, Chao-Liang Wu and Gia-Shing Shieh

XPO1-dependent nuclear export as a target for cancer therapy

Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport ...

Authors: Nancy G. Azizian and Yulin Li

Emerging agents that target signaling pathways in cancer stem cells

Cancer stem cells (CSCs) contribute to the initiation, recurrence, and metastasis of cancer; however, there are still no drugs targeting CSCs in clinical application. There are several signaling pathways playi...

Authors: Yue Yang, Xiaoman Li, Ting Wang, Qianqian Guo, Tao Xi and Lufeng Zheng

Biomarker-driven management strategies for peripheral T cell lymphoma

Peripheral T cell lymphomas are heterogeneous diseases which remain treatment challenges. Recent advances in molecular and genomic profiling have provided unprecedented insight into disease pathogenesis driven...

Authors: Erin Mulvey and Jia Ruan

Emerging therapeutic agents for advanced non-small cell lung cancer

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances i...

Authors: Ruqin Chen, Rami Manochakian, Lauren James, Abdel-Ghani Azzouqa, Huashan Shi, Yan Zhang, Yujie Zhao, Kexun Zhou and Yanyan Lou

Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer

Gastrointestinal cancer, the most common solid tumor, has a poor prognosis. With the development of high-throughput sequencing and detection technology, recent studies have suggested that many chemical modific...

Authors: Qiang Wang, Wei Geng, Huimin Guo, Zhangding Wang, Kaiyue Xu, Chen Chen and Shouyu Wang

Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Peripheral T cell lymphomas form a heterogeneous group with a usually dismal prognostic. The place of allogeneic stem cell transplantation to treat PTCL is debated.

Authors: Anne-Claire Mamez, Axelle Dupont, Didier Blaise, Patrice Chevallier, Edouard Forcade, Patrice Ceballos, Mohamad Mohty, Felipe Suarez, Yves Beguin, Regis Peffault De Latour, Marie-Thérèse Rubio, Olivier Tournilhac and Stéphanie Nguyen

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials

Immune checkpoint inhibitors, especially the programmed cell death receptor-1/ligand 1 (PD-1/L1) inhibitors, displayed promising efficacy in several solid tumor types and hematological malignancies. Data relat...

Authors: Antoine Italiano, Carine Bellera and Sandra D’Angelo

Gene modification strategies for next-generation CAR T cells against solid cancers

Immunotherapies have become the backbone of cancer treatment. Among them, chimeric antigen receptor (CAR) T cells have demonstrated great success in the treatment of hematological malignancies. However, CAR T ...

Authors: Yonggui Tian, Yilu Li, Yupei Shao and Yi Zhang

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

An amendment to this paper has been published and can be accessed via the original article.

Authors: Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Xiao Han, Yang Liu, Wenying Zhang, Chunmeng Wang, Yajing Zhang, Meixia Chen, Qingming Yang, Yao Wang and Weidong Han

Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1

Human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) as a postremission treatment for standard risk Philadelphia chromosome-negative acute lymphoblastic leukemia (SR Ph-ALL) in th...

Authors: Meng Lv, Qian Jiang, Dao-Bin Zhou, Yu Hu, Dai-Hong Liu, De-Pei Wu, Jing-Bo Wang, Hao Jiang, Jing Wang, Ying-jun Chang, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu, Kai-Yan Liu and Xiao-Jun Huang

Anticancer drug R&D landscape in China

Authors: Shen Zhao, Hongyun Zhao, Cheng Lv, Jifang Gong, Jian Zhang, Wenfeng Fang, Jin Li, Xichun Hu, Yi Ba, Binghe Xu, Yanqiao Zhang, Yun Fan, Kunyan Li, Xiaoyuan Chen, Zhimin Yang, Lin Shen…

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly small-molecule inhibitor) of th...

Authors: Xin Li and Yongcheng Song

Relative survival in early-stage cancers in the Netherlands: a population-based study

In this nationwide, population-based study, we assessed 10-year relative survival among 225,305 patients with ten early-stage cancers diagnosed in the Netherlands during 2004–2015. This study aimed to ascertai...

Authors: Avinash G. Dinmohamed, Valery E. P. P. Lemmens, Ignace H. J. T. de Hingh and Otto Visser

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocyt...

Authors: Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Jianfeng Zhou, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Meng Ji, Haiyi Guo, Jane Huang, William Novotny, Shibao Feng…

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event related to camrelizumab, an i...

Authors: Feng Wang, Shukui Qin, Xinchen Sun, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang, Xiaoyan Lin, Xiaoming Chen, Enxiao Li, Linna Wang…

Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT

The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched ...

Authors: Jaime Sanz, Jacques-Emmanuel Galimard, Myriam Labopin, Boris Afanasyev, Emanuele Angelucci, Fabio Ciceri, Didier Blaise, Jan J. Cornelissen, Ellen Meijer, J. L. Diez-Martin, Yener Koc, Montserrat Rovira, Luca Castagna, Bipin Savani, Annalisa Ruggeri, Arnon Nagler…

How to select IgG subclasses in developing anti-tumor therapeutic antibodies

The intact antibody of human immunoglobulin (IgG) is composed of the fragment for antigen binding (Fab) and the crystallizable fragment (Fc) for binding of Fcγ receptors. Among the four subclasses of human IgG...

Authors: Jifeng Yu, Yongping Song and Wenzhi Tian

Correction to: MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming

An amendment to this paper has been published and can be accessed via the original article.

Authors: Yang Liu, Li-Li Lu, Duo Wen, Dong-Li Liu, Li-Li Dong, Dong-Mei Gao, Xin-Yu Bian, Jian Zhou, Jia Fan and Wei-Zhong Wu

Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis

The novel coronavirus (2019-nCoV) is an emerging causative agent that was first described in late December 2019 and causes a severe respiratory infection in humans. Notably, many of affected patients of COVID-...

Authors: Peiwei Chai, Jie Yu, Shengfang Ge, Renbing Jia and Xianqun Fan

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study

Consolidative allogeneic hematopoietic stem cell transplantation is a controversial option for patients with relapsed/refractory acute lymphoblastic leukemia after chimeric antigen receptor T cell (CAR-T) ther...

Authors: Houli Zhao, Jieping Wei, Guoqing Wei, Yi Luo, Jimin Shi, Qu Cui, Mingfeng Zhao, Aibin Liang, Qing Zhang, Jianmin Yang, Xin Li, Jing Chen, Xianmin Song, Hongmei Jing, Yuhua Li, Siguo Hao…

The application and prospect of CDK4/6 inhibitors in malignant solid tumors

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which block the transition from the G1 to S phase of the cell cycle by interfering with Rb phosphorylation and E2F release, have shown potent antitumor activity...

Authors: Qi Du, Xiang Guo, Miao Wang, Yongfu Li, Xiaoyi Sun and Qin Li

Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation

Aberrant activation of DNA damage response (DDR) is a major cause of chemoresistance in colorectal cancer (CRC). CHK1 is upregulated in CRC and contributes to therapeutic resistance. We investigated the upstre...

Authors: Xinfang Yu, Wei Li, Haidan Liu, Qipan Deng, Xu Wang, Hui Hu, Zijun Y. Xu-Monette, Wei Xiong, Zhongxin Lu, Ken H. Young, Wei Wang and Yong Li

Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer

Ovarian cancer is one of the most lethal gynecologic malignancies reported throughout the world. The initial, standard-of-care, adjuvant chemotherapy in epithelial ovarian cancer is usually a platinum drug, su...

Authors: Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak and Aneta Rogalska

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma

Rituximab in combination with chemotherapy has shown efficacy in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years. HLX01 was developed as the rituximab biosimilar following a stepwise...

Authors: Yuankai Shi, Yongping Song, Yan Qin, Qingyuan Zhang, Xiaohong Han, Xiaonan Hong, Dong Wang, Wei Li, Yang Zhang, Jifeng Feng, Jianmin Yang, Huilai Zhang, Chuan Jin, Yu Yang, Jianda Hu, Zhao Wang…

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

Rearranged during transfection (RET) has been proven to be a tumorigenic target in non-small cell lung cancers (NSCLCs). In RET-rearranged NSCLCs, molecular features and their impact on prognosis were not well il...

Authors: Chang Lu, Xiao-Rong Dong, Jun Zhao, Xu-Chao Zhang, Hua-Jun Chen, Qing Zhou, Hai-Yan Tu, Xing-Hao Ai, Xiao-Feng Chen, Gai-Li An, Jun Bai, Jin-Lu Shan, Yi-Na Wang, Shuan-Ying Yang, Xiang Liu, Wu Zhuang…

An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination

Current acute myeloid leukemia (AML) therapy fails to eliminate quiescent leukemic blasts in the bone marrow, leading to about 50% of patient relapse by increasing AML burden in the bone marrow, blood, and ext...

Authors: Victor Pallarès, Ugutz Unzueta, Aïda Falgàs, Laura Sánchez-García, Naroa Serna, Alberto Gallardo, Gordon A. Morris, Lorena Alba-Castellón, Patricia Álamo, Jorge Sierra, Antonio Villaverde, Esther Vázquez, Isolda Casanova and Ramon Mangues

m⁶A-binding proteins: the emerging crucial performers in epigenetics

N⁶-methyladenosine (m⁶A) is a well-known post-transcriptional modification that is the most common type of methylation in eukaryotic mRNAs. The regulation of m⁶A is dynamic and reversible, which is erected by m⁶A...

Authors: Yanchun Zhao, Yuanfei Shi, Huafei Shen and Wanzhuo Xie

CRISPR/CAS9-mediated knockout of Abi1 inhibits p185^Bcr-Abl-induced leukemogenesis and signal transduction to ERK and PI3K/Akt pathways

Abl interactor 1 (Abi1) is a downstream target of Abl tyrosine kinases and a component of the WAVE regulatory complex (WRC) that plays an important role in regulating actin cytoskeleton remodeling and membrane...

Authors: James Faulkner, Peixin Jiang, Delaney Farris, Ryan Walker and Zonghan Dai

Targeting epigenetics in sarcomas through EZH2 inhibition

Soft-tissue sarcomas represent a heterogeneous group of diseases with distinct genetic and clinical features accounting for up to 1% of cancer in adults and 15% of cancer in children. Epithelioid sarcoma is an...

Authors: Antoine Italiano

CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110

In the search for novel antibody-drug conjugates (ADCs) with therapeutic potential, it is imperative to identify novel targets to direct the antibody moiety. CD13 seems an attractive ADC target as it shows a d...

Authors: Juan Manuel Domínguez, Gema Pérez-Chacón, María José Guillén, María José Muñoz-Alonso, Beatriz Somovilla-Crespo, Danay Cibrián, Bárbara Acosta-Iborra, Magdalena Adrados, Cecilia Muñoz-Calleja, Carmen Cuevas, Francisco Sánchez-Madrid, Pablo Avilés and Juan M. Zapata

Mechanisms and rejuvenation strategies for aged hematopoietic stem cells

Hematopoietic stem cell (HSC) aging, which is accompanied by reduced self-renewal ability, impaired homing, myeloid-biased differentiation, and other defects in hematopoietic reconstitution function, is a hot ...

Authors: Xia Li, Xiangjun Zeng, Yulin Xu, Binsheng Wang, Yanmin Zhao, Xiaoyu Lai, Pengxu Qian and He Huang

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-m...

Authors: Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Xiao Han, Yang Liu, Wenying Zhang, Chunmeng Wang, Yajing Zhang, Meixia Chen, Qingming Yang, Yao Wang and Weidong Han

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Cancer immunotherapy has reached a critical point, now that immune checkpoint inhibitors and two CAR-T products have received market approval in treating 16 types of cancers and 1 tissue-agnostic cancer indica...

Authors: Chongxian Pan, Hongtao Liu, Elizabeth Robins, Wenru Song, Delong Liu, Zihai Li and Lei Zheng

Expression patterns of immune checkpoints in acute myeloid leukemia

Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy is still not available for acute myeloid leukemia (AML). One major issu...

Authors: Cunte Chen, Chaofeng Liang, Shunqing Wang, Chi Leong Chio, Yuping Zhang, Chengwu Zeng, Shaohua Chen, Caixia Wang and Yangqiu Li

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study

Previous reports suggest a benefit associated with haploidentical donor transplantation (HIDT) compared to matched sibling donor transplantation (MSDT) in certain contexts, and the choice of optimal candidates...

Authors: Ying-Jun Chang, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei-Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu and Xiao-Jun Huang

The design and development of covalent protein-protein interaction inhibitors for cancer treatment

Protein-protein interactions (PPIs) are central to a variety of biological processes, and their dysfunction is implicated in the pathogenesis of a range of human diseases, including cancer. Hence, the inhibiti...

Authors: Sha-Sha Cheng, Guan-Jun Yang, Wanhe Wang, Chung-Hang Leung and Dik-Lung Ma

The role of cancer-derived microRNAs in cancer immune escape

During malignant transformation, accumulated somatic mutations endow cancer cells with increased invasiveness and immunogenicity. Under selective pressure, these highly immunogenic cancer cells develop multipl...

Authors: Ming Yi, Linping Xu, Ying Jiao, Suxia Luo, Anping Li and Kongming Wu

HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression

Aerobic glycolysis is a hallmark of metabolic reprogramming that contributes to tumor progression. However, the mechanisms regulating expression of glycolytic genes in neuroblastoma (NB), the most common extra...

Authors: Huajie Song, Dan Li, Xiaojing Wang, Erhu Fang, Feng Yang, Anpei Hu, Jianqun Wang, Yanhua Guo, Yang Liu, Hongjun Li, Yajun Chen, Kai Huang, Liduan Zheng and Qiangsong Tong

Correction to: Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer

The original article [1] contains an error in Fig. 5b whereby two panels have been mistakenly duplicated. The correct version of Fig. 5b can be viewed ahead alongside the rest of Fig. 5.

Authors: Shaoquan Zheng, Lu Yang, Yutian Zou, Jie-ying Liang, Peng Liu, Guanfeng Gao, Anli Yang, Hailin Tang and Xiaoming Xie

Identification of cross-talk between m⁶A and 5mC regulators associated with onco-immunogenic features and prognosis across 33 cancer types

Methylation of RNA and DNA, notably in the forms of N6-methyladenosine (m⁶A) and 5-methylcytosine (5mC) respectively, plays crucial roles in diverse biological processes. Currently, there is a lack of knowledge r...

Authors: Yu-Tong Chen, Jia-Yi Shen, Dong-Ping Chen, Chen-Fei Wu, Rui Guo, Pan-Pan Zhang, Jia-Wei Lv, Wen-Fei Li, Zi-Xian Wang and Yu-Pei Chen

Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group

Mantle cell lymphoma (MCL) is a B cell malignancy that can be aggressive and with a poor prognosis; the clinical course is heterogeneous. The epidemiology of MCL in Asia is not well documented but appears to c...

Authors: Dok Hyun Yoon, Junning Cao, Tsai-Yun Chen, Koji Izutsu, Seok Jin Kim, Yok Lam Kwong, Tong Yu Lin, Lim Soon Thye, Bing Xu, Deok Hwan Yang and Won Seog Kim

Treating non-responders: pitfalls and implications for cancer immunotherapy trial design

Conventional trial design and analysis strategies fail to address the typical challenge of immune-oncology (IO) studies: only a limited percentage of treated patients respond to the experimental treatment. Tre...

Authors: Zhenzhen Xu, Yongsoek Park, Ke Liu and Bin Zhu

Vasculogenic mimicry in carcinogenesis and clinical applications

Distinct from classical tumor angiogenesis, vasculogenic mimicry (VM) provides a blood supply for tumor cells independent of endothelial cells. VM has two distinct types, namely tubular type and patterned matr...

Authors: Qingxi Luo, Jun Wang, Wenyuan Zhao, Zhenzi Peng, Xianyu Liu, Bin Li, Heng Zhang, Bin Shan, Chunfang Zhang and Chaojun Duan

Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data

Compared with HLA-matched sibling donor (MSD) transplant, the outcomes of haploidentical donor (HID) transplant for refractory acute leukemia need to be further explored. In this study, we compared the outcome...

Authors: Sijian Yu, Fen Huang, Zhiping Fan, Li Xuan, Danian Nie, Yajing Xu, Ting Yang, Shunqing Wang, Zujun Jiang, Na Xu, Ren Lin, Jieyu Ye, Dongjun Lin, Jing Sun, Xiaojun Huang, Yu Wang…

Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer with highly invasive ability and metastatic nature to the lymph nodes. Long non-coding RNAs (lncRNAs) have been widely explor...

Authors: Shaoquan Zheng, Lu Yang, Yutian Zou, Jie-ying Liang, Peng Liu, Guanfeng Gao, Anli Yang, Hailin Tang and Xiaoming Xie